Transgender Women Living with HIV Frequently Take Antiretroviral Therapy and/or Feminizing Hormone Therapy Differently Than Prescribed Due to Drug-Drug Interaction Concerns

Hannan M. Braun; Jury Candelario; Courtney L. Hanlon; Eddy R. Segura; Jesse L. Clark; Judith S. Currier; Jordan E. Lake

doi:10.1089/lgbt.2017.0057

Transgender Women Living with HIV Frequently Take Antiretroviral Therapy and/or Feminizing Hormone Therapy Differently Than Prescribed Due to Drug-Drug Interaction Concerns

Hannan M. Braun, Jury Candelario, Courtney L. Hanlon, Eddy R. Segura, Jesse L. Clark, Judith S. Currier, Jordan E. Lake

Research output: Contribution to journal › Article › peer-review

41 Scopus citations

Abstract

Purpose: Both hormone therapy (HT) and antiretroviral therapy (ART) can be lifesaving for transgender women (TW) living with HIV, but each has side effects and potential drug-drug interactions (DDI). We assessed how concerns about HT-ART interactions affect treatment adherence. Methods: This study used a cross-sectional survey of TW (n = 87) in Los Angeles, CA. Results: Fifty-four percent were living with HIV; 64% used HT. Only 49% of TW living with HIV discussed ART-HT DDI with their provider; 40% reported not taking ART (12%), HT (12%), or both (16%) as directed due to DDI concerns. Conclusion: Imperfect HT/ART use and limited provider communication suggests a need for improved HT-ART integration.

Original language	English
Pages (from-to)	371-375
Number of pages	5
Journal	LGBT Health
Volume	4
Issue number	5
DOIs	https://doi.org/10.1089/lgbt.2017.0057
State	Published - Oct 2017
Externally published	Yes

Keywords

HIV
antiretroviral therapy
health disparities
medication adherence
transgender

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1089/lgbt.2017.0057

Cite this

@article{38e459cf3ea34e67819d10cf9d10d4d9,

title = "Transgender Women Living with HIV Frequently Take Antiretroviral Therapy and/or Feminizing Hormone Therapy Differently Than Prescribed Due to Drug-Drug Interaction Concerns",

abstract = "Purpose: Both hormone therapy (HT) and antiretroviral therapy (ART) can be lifesaving for transgender women (TW) living with HIV, but each has side effects and potential drug-drug interactions (DDI). We assessed how concerns about HT-ART interactions affect treatment adherence. Methods: This study used a cross-sectional survey of TW (n = 87) in Los Angeles, CA. Results: Fifty-four percent were living with HIV; 64% used HT. Only 49% of TW living with HIV discussed ART-HT DDI with their provider; 40% reported not taking ART (12%), HT (12%), or both (16%) as directed due to DDI concerns. Conclusion: Imperfect HT/ART use and limited provider communication suggests a need for improved HT-ART integration.",

keywords = "HIV, antiretroviral therapy, health disparities, medication adherence, transgender",

author = "Braun, {Hannan M.} and Jury Candelario and Hanlon, {Courtney L.} and Segura, {Eddy R.} and Clark, {Jesse L.} and Currier, {Judith S.} and Lake, {Jordan E.}",

year = "2017",

month = oct,

doi = "10.1089/lgbt.2017.0057",

language = "Ingl{\'e}s",

volume = "4",

pages = "371--375",

journal = "LGBT Health",

issn = "2325-8292",

publisher = "Mary Ann Liebert Inc.",

number = "5",

}

TY - JOUR

T1 - Transgender Women Living with HIV Frequently Take Antiretroviral Therapy and/or Feminizing Hormone Therapy Differently Than Prescribed Due to Drug-Drug Interaction Concerns

AU - Braun, Hannan M.

AU - Candelario, Jury

AU - Hanlon, Courtney L.

AU - Segura, Eddy R.

AU - Clark, Jesse L.

AU - Currier, Judith S.

AU - Lake, Jordan E.

PY - 2017/10

Y1 - 2017/10

N2 - Purpose: Both hormone therapy (HT) and antiretroviral therapy (ART) can be lifesaving for transgender women (TW) living with HIV, but each has side effects and potential drug-drug interactions (DDI). We assessed how concerns about HT-ART interactions affect treatment adherence. Methods: This study used a cross-sectional survey of TW (n = 87) in Los Angeles, CA. Results: Fifty-four percent were living with HIV; 64% used HT. Only 49% of TW living with HIV discussed ART-HT DDI with their provider; 40% reported not taking ART (12%), HT (12%), or both (16%) as directed due to DDI concerns. Conclusion: Imperfect HT/ART use and limited provider communication suggests a need for improved HT-ART integration.

AB - Purpose: Both hormone therapy (HT) and antiretroviral therapy (ART) can be lifesaving for transgender women (TW) living with HIV, but each has side effects and potential drug-drug interactions (DDI). We assessed how concerns about HT-ART interactions affect treatment adherence. Methods: This study used a cross-sectional survey of TW (n = 87) in Los Angeles, CA. Results: Fifty-four percent were living with HIV; 64% used HT. Only 49% of TW living with HIV discussed ART-HT DDI with their provider; 40% reported not taking ART (12%), HT (12%), or both (16%) as directed due to DDI concerns. Conclusion: Imperfect HT/ART use and limited provider communication suggests a need for improved HT-ART integration.

KW - HIV

KW - antiretroviral therapy

KW - health disparities

KW - medication adherence

KW - transgender

UR - http://www.scopus.com/inward/record.url?scp=85031308064&partnerID=8YFLogxK

U2 - 10.1089/lgbt.2017.0057

DO - 10.1089/lgbt.2017.0057

M3 - Artículo

C2 - 28876170

AN - SCOPUS:85031308064

SN - 2325-8292

VL - 4

SP - 371

EP - 375

JO - LGBT Health

JF - LGBT Health

IS - 5

ER -

Transgender Women Living with HIV Frequently Take Antiretroviral Therapy and/or Feminizing Hormone Therapy Differently Than Prescribed Due to Drug-Drug Interaction Concerns

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this